Haema_Octapharma_01_2016_Figure 08

Figure 8. Summary of personalised prophylaxis study with Nuwiq ® (Human-cl rhFVIII). † Based on interim data for 30 patients. ‡ Patient with 2 adverse events (malaise / dizziness) which occurred after the same infusion. * During last 2-months of personalised prophylaxis.

Figure 8. Summary of personalised prophylaxis study with Nuwiq® (Human-cl rhFVIII). † Based on interim data for 30 patients. ‡ Patient with 2 adverse events (malaise / dizziness) which occurred after the same infusion. * During last 2-months of personalised prophylaxis. 56